Abrysvo
FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines
RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy
GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval
GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Pfizer Strengthens Case for RSV Vaccine with Positive Data in Vulnerable Adults
Pfizer, RSV vaccine, Abrysvo, immunocompromised adults, clinical trial, immune responses, regulatory approval
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy